Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Cell Physiol ; 227(11): 3593-602, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22287283

ABSTRACT

The lymphatic vasculature is essential for the maintenance of tissue fluid, immune surveillance, and dissemination of metastasis. Recently, several models for lymphatic vascular research and markers specific for lymphatic endothelium have been characterized. Despite these significant achievements, our understanding of the early lymphatic development is still rather limited. The purpose of the study was to further define early lymphatic differentiation regulatory pathways. In the present study, we have developed conditions leading to lymphatic endothelial cell differentiation under both serum-rich and serum-free conditions, using the coculture system of Flk-1-positive vascular precursors derived from murine embryonic stem (ES) cells grown on an OP9 stromal cell layer. In this work, we also identified Transforming Growth Factor-ß1 (TGFß1) as a negative regulator of lymphvasculogenesis from ES-derived vascular progenitors. Finally, we could show that TGFß1 addition decreases COUP-TFII and Sox18 mRNA levels, which are two transcription factors known to be involved in early lymphatic endothelial differentiation. Taken together these findings support the concept that manipulating the TGFß signaling pathway may represent an interesting target to favor lymphatic endothelial cell expansion for cell replacement strategies.


Subject(s)
Cell Differentiation , Embryonic Stem Cells/cytology , Endothelial Cells , Transforming Growth Factor beta1/metabolism , Animals , COUP Transcription Factor II/metabolism , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Line , Cell Lineage/genetics , Coculture Techniques , Culture Media, Serum-Free , Embryonic Stem Cells/physiology , Endothelial Cells/cytology , Endothelial Cells/physiology , Gene Expression Regulation, Developmental/drug effects , Glycoproteins/metabolism , Membrane Transport Proteins , Mice , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , SOXF Transcription Factors/metabolism , Signal Transduction , Stromal Cells/cytology , Transforming Growth Factor beta1/genetics , Transforming Growth Factor beta1/pharmacology , Vascular Endothelial Growth Factor Receptor-2/metabolism
2.
J Biol Chem ; 287(10): 7556-72, 2012 Mar 02.
Article in English | MEDLINE | ID: mdl-22194609

ABSTRACT

Adherens junctions are required for vascular endothelium integrity. These structures are formed by the clustering of the homophilic adhesive protein VE-cadherin, which recruits intracellular partners, such as ß- and α-catenins, vinculin, and actin filaments. The dogma according to which α-catenin bridges cadherin·ß-catenin complexes to the actin cytoskeleton has been challenged during the past few years, and the link between the VE-cadherin·catenin complex and the actin cytoskeleton remains unclear. Recently, epithelial protein lost in neoplasm (EPLIN) has been proposed as a possible bond between the E-cadherin·catenin complex and actin in epithelial cells. Herein, we show that EPLIN is expressed at similar levels in endothelial and epithelial cells and is located at interendothelial junctions in confluent cells. Co-immunoprecipitation and GST pulldown experiments provided evidence that EPLIN interacts directly with α-catenin and tethers the VE-cadherin·catenin complex to the actin cytoskeleton. In the absence of EPLIN, vinculin was delocalized from the junctions. Furthermore, suppression of actomyosin tension using blebbistatin triggered a similar vinculin delocalization from the junctions. In a Matrigel assay, EPLIN-depleted endothelial cells exhibited a reduced capacity to form pseudocapillary networks because of numerous breakage events. In conclusion, we propose a model in which EPLIN establishes a link between the cadherin·catenin complex and actin that is independent of actomyosin tension. This link acts as a mechanotransmitter, allowing vinculin binding to α-catenin and formation of a secondary molecular bond between the adherens complex and the cytoskeleton through vinculin. In addition, we provide evidence that the EPLIN clutch is necessary for stabilization of capillary structures in an angiogenesis model.


Subject(s)
Actin Cytoskeleton/metabolism , Capillaries/metabolism , Cytoskeletal Proteins/metabolism , Endothelial Cells/metabolism , Models, Biological , Neovascularization, Physiologic/physiology , alpha Catenin/metabolism , Actin Cytoskeleton/genetics , Adherens Junctions/genetics , Adherens Junctions/metabolism , Animals , Antigens, CD/genetics , Antigens, CD/metabolism , Caco-2 Cells , Cadherins/genetics , Cadherins/metabolism , Capillaries/cytology , Cytoskeletal Proteins/genetics , Dogs , Endothelial Cells/cytology , Epithelial Cells/cytology , Epithelial Cells/metabolism , Humans , Mechanotransduction, Cellular/physiology , Multiprotein Complexes/genetics , Multiprotein Complexes/metabolism , Vinculin/genetics , Vinculin/metabolism , alpha Catenin/genetics
3.
J Biol Chem ; 286(17): 15195-204, 2011 Apr 29.
Article in English | MEDLINE | ID: mdl-21402705

ABSTRACT

Protocadherins are a group of transmembrane proteins with homophilic binding activity, members of the cadherin superfamily. Apart from their role in adhesion, the cellular functions of protocadherins are essentially unknown. Protocadherin (PCDH)12 was previously identified in invasive trophoblasts and endothelial and mesangial cells in the mouse. Invalidation studies revealed that the protein was required for optimal placental development. In this article, we show that its human homolog is abundantly expressed in various trophoblast subtypes of the human placenta and at lower levels in endothelial cells. We demonstrate that PCDH12 is shed at high rates in vitro. The shedding mechanism depends on ADAM10 and results in reduced cellular adhesion in a cell migration assay. PCDH12 is subsequently cleaved by the γ-secretase complex, and its cytoplasmic domain is rapidly degraded by the proteasome. PCDH12 shedding is regulated by interlinked intracellular pathways, including those involving protein kinase C, PI3K, and cAMP, that either increase or inhibit cleavage. In endothelial cells, VEGF, prostaglandin E(2), or histamine regulates PCDH12 shedding. The extracellular domain of PCDH12 was also detected in human serum and urine, thus providing evidence of PCDH12 shedding in vivo. Importantly, we observed an increase in circulating PCDH12 in pregnant women who later developed a pre-eclampsia, a frequent pregnancy syndrome and a major cause of maternal and fetal morbidity and mortality. In conclusion, we speculate that, like in mice, PCDH12 may play an important role in human placental development and that proteolytic cleavage in response to external factors, such as cytokines and pathological settings, regulates its activity.


Subject(s)
ADAM Proteins/metabolism , Amyloid Precursor Protein Secretases/metabolism , Cadherins/metabolism , Membrane Proteins/metabolism , Pre-Eclampsia/metabolism , ADAM10 Protein , Endothelial Cells/chemistry , Female , Humans , Hydrolysis , Peptide Fragments/blood , Peptide Fragments/urine , Placentation , Pregnancy , Protocadherins , Trophoblasts/chemistry , Up-Regulation
4.
Physiol Genomics ; 34(2): 193-204, 2008 Jul 15.
Article in English | MEDLINE | ID: mdl-18477666

ABSTRACT

Protocadherins are transmembrane proteins exhibiting homophilic adhesive activities through their extracellular domain. Protocadherin 12 (Pcdh12) is expressed in angiogenic endothelial cells, mesangial cells of kidney glomeruli, and glycogen cells of the mouse placenta. To get insight into the role of this protein in vivo, we analyzed PCDH12-deficient mice and investigated their placental phenotype. The mice were alive and fertile; however, placental and embryonic sizes were reduced compared with wild-type mice. We observed defects in placental layer segregation and a decreased vascularization of the labyrinth associated with a reduction in cell density in this layer. To understand the molecular events responsible for the phenotypic alterations observed in Pcdh12(-/-) placentas, we analyzed the expression profile of embryonic day 12.5 mutant placentas compared with wild-type placentas, using pangenomic chips: 2,289 genes exhibited statistically significant changes in expressed levels due to loss of PCDH12. Functional grouping of modified genes was obtained by GoMiner software. Gene clusters that contained most of the differentially expressed genes were those involved in tissue morphogenesis and development, angiogenesis, cell-matrix adhesion and migration, immune response, and chromatin remodeling. Our data show that loss of PCDH12 leads to morphological alterations of the placenta and to notable changes in its gene expression profile. Specific genes emerging from the microarray screen support the biological modifications observed in PCDH12-deficient placentas.


Subject(s)
Cadherins/deficiency , Gene Expression Profiling , Morphogenesis , Placenta/embryology , Placenta/metabolism , Animals , Animals, Newborn , Cadherins/metabolism , Cell Adhesion , Cell Movement , Decidua/cytology , Decidua/metabolism , Female , Glycogen/metabolism , Mice , Organ Size , Placenta/cytology , Pregnancy , Protocadherins , Reverse Transcriptase Polymerase Chain Reaction
5.
BMC Biotechnol ; 7: 20, 2007 Apr 16.
Article in English | MEDLINE | ID: mdl-17437635

ABSTRACT

BACKGROUND: Angiogenesis assays are important tools for the identification of regulatory molecules and the potential development of therapeutic strategies to modulate neovascularization. Although numerous in vitro angiogenesis models have been developed in the past, they exhibit limitations since they do not recapitulate the entire angiogenic process or correspond to multi-step procedures that are not easy to use. Convenient, reliable, easily quantifiable and physiologically relevant assays are still needed for pharmacological screenings of angiogenesis. RESULTS: Here, we have optimized an angiogenesis model based on ES cell differentiation for screening experiments. We have established conditions leading to angiogenic sprouting of embryoid bodies during ES cell differentiation in type I three-dimensional collagen gels. Immunostaining experiments carried out during these cultures showed the formation of numerous buds comprising CD31 positive cells, after 11 days of culture of ES cells. Moreover, this one-step model has been validated in response to activators and inhibitors of angiogenesis. Sprouting was specifically stimulated in the presence of VEGF and FGF2. Alternatively, endothelial sprouting induced by angiogenic activators was inhibited by angiogenesis inhibitors such as angiostatin, TGFbeta and PF4. Sprouting angiogenesis can be easily quantified by image analysis after immunostaining of endothelial cells with CD31 pan-endothelial marker. CONCLUSION: Taken together, these data clearly validate that this one-step ES differentiation model constitutes a simple and versatile angiogenesis system that should facilitate, in future investigations, the screening of both activators and inhibitors of angiogenesis.


Subject(s)
Angiogenesis Inducing Agents/administration & dosage , Angiogenesis Inhibitors/administration & dosage , Endothelial Cells/cytology , Endothelial Cells/drug effects , Neovascularization, Physiologic/drug effects , Stem Cells/cytology , Stem Cells/drug effects , Animals , Biological Assay/methods , Cell Differentiation/drug effects , Cell Line , Endothelial Cells/physiology , Mice , Neovascularization, Physiologic/physiology , Stem Cells/physiology
6.
J Cell Physiol ; 213(1): 27-35, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17450519

ABSTRACT

During embryogenesis, the formation of blood vessels proceeds by both vasculogenesis and angiogenesis. Both processes appear to be finely regulated. To date, factors and genes involved in the negative regulation of embryonic vasculogenesis remain largely unknown. Angiostatin is a proteolytic fragment of plasminogen that acts as an inhibitor of angiogenesis. In this study, we analyzed the potential role of angiostatin during early stages of embryonic stem (ES) cell endothelial in vitro differentiation, as a model of vasculogenesis. We found an early expression of the known angiostatin binding sites (angiomotin, alphav integrin and c-met oncogene) during ES cell differentiation. Nevertheless, we did not detect any significant effect of angiostatin on mesoderm induction and on differentiation commitment into cells of the endothelial lineage. In both control and angiostatin-treated conditions, the temporal and extent of formation of the Flk1 positive and Flk-1/CD31 (PECAM-1) positive cell populations were not significantly different. Quantitative RT-PCR experiments of endothelial gene expression (Flk-1, PECAM-1 and tie-2) confirm a lack of interference with early steps of endothelial differentiation in embryoid bodies. No evidence for an angiostatin effect on endothelial cord-like formation could be detected at later differentiation stages. On the other hand, angiostatin inhibits vascular endothelial growth factor-induced endothelial sprouting from embryoid bodies cultured in three dimensional type I collagen gels. Taken together, these findings support a selective inhibitory effect on the sprouting angiogenesis response for angiostatin during embryonic vascular development.


Subject(s)
Angiostatins/pharmacology , Blood Vessels/drug effects , Blood Vessels/embryology , Embryonic Stem Cells/cytology , Embryonic Stem Cells/drug effects , Angiostatins/metabolism , Animals , Base Sequence , Binding Sites/genetics , Blood Vessels/metabolism , Cell Differentiation/drug effects , Cell Line , DNA Primers/genetics , Embryonic Stem Cells/metabolism , Gene Expression Regulation, Developmental , Mice , Neovascularization, Physiologic , Vascular Endothelial Growth Factor A
7.
Oncogene ; 24(18): 2992-3001, 2005 Apr 21.
Article in English | MEDLINE | ID: mdl-15735710

ABSTRACT

Vascular endothelial (VE)-cadherin is exclusively expressed at interendothelial junctions of normal and tumour vessels. In this report, we characterized the transcriptional activity of the human VE-cadherin promoter. Transient transfection assays revealed that sequences at positions --1135/-744 and -166/-5 base pairs are critical for promoter activity in endothelial cells. We show that specific sequences in the proximal region interact with Ets and Sp1 family members. Transgenic mice were created and the human VE-cadherin promoter was able to confer correct temporal and spatial expression on the LacZ gene in embryos. In adults, the transgene was specifically and strongly expressed in the lung, heart, ovary, spleen and kidney glomeruli, whereas expression was weak or absent in the vasculature of other organs, including the brain, thymus, liver and skeletal muscle. Neovessels in tumour grafts and Matrigel implants harboured strong stainings, indicating that promoter activity is enhanced in angiogenic situations. Furthermore, Matrigel and transfection assays showed that VE-cadherin promoter is subjected to bFGF induction. Transgene expression was also noticed in extravascular sites of the central nervous system, suggesting that silencer elements may be located elsewhere in the gene. These results are a first step towards addressing the organ- and tumour-specific regulation of the VE-cadherin gene.


Subject(s)
Cadherins/genetics , Gene Expression Regulation, Neoplastic/physiology , Neoplasms/metabolism , Neovascularization, Pathologic/metabolism , Promoter Regions, Genetic , Animals , Antigens, CD , Base Sequence , Cadherins/metabolism , Humans , Mice , Mice, Transgenic , Molecular Sequence Data , Neoplasms/genetics , Neovascularization, Pathologic/genetics , Organ Specificity
8.
J Mol Endocrinol ; 34(1): 127-37, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15691883

ABSTRACT

Vascular endothelial-cadherin (VE-cadherin) is an endothelial cell-specific adhesion protein that is localised at cell-cell contacts. This molecule is an important determinant of vascular architecture and endothelial cell survival. In the adrenal cortex, steroidogenic and endothelial cells form a complex architecture. The adrenocorticotrophin hormone (ACTH) regulates gland homeostasis whose secretion is subjected to a negative feedback by adrenocorticosteroids. The aim of the present study was to determine whether VE-cadherin expression in the adrenal gland was regulated by hormonal challenge. We demonstrated that VE-cadherin protein levels were dramatically decreased (23.5+/-3.7%) by dexamethasone injections in the mouse and were restored by ACTH within 7 days (94.9+/-18.6%). Flow cytometry analysis of adrenal cells showed that the ratios of endothelial versus total adrenal cells were identical (35%) in dexamethasone- or ACTH-treated or untreated mice, suggesting that VE-cadherin expression could be regulated by ACTH. We demonstrate the existence of a transcriptional regulation of the VE-cadherin gene using transgenic mice carrying the chloramphenicol acetyl transferase gene under the control of the VE-cadherin promoter. Indeed, the promoter activity in the adrenals, but not in the lung or liver, was decreased in response to dexamethasone treatment (40+/-1.3%) and was partially restored after gland regeneration by ACTH injection (82+/-3%). In conclusion, our results show that transcription of a specific endothelial gene is controlled by the hypothalamo-pituitary axis and the data expand the knowledge regarding the role of ACTH in the regulation of the adrenal vascular network.


Subject(s)
Adrenal Glands/metabolism , Adrenocorticotropic Hormone/metabolism , Cadherins/genetics , Animals , Antigens, CD , Cadherins/biosynthesis , Endothelium/metabolism , Flow Cytometry , Mice , Promoter Regions, Genetic
9.
Exp Cell Res ; 302(1): 48-60, 2005 Jan 01.
Article in English | MEDLINE | ID: mdl-15541725

ABSTRACT

Protocadherin 12 protein (PCDH12, VE-cadherin 2) is a cell adhesion molecule that has been isolated from endothelial cells. Here, we have used Northern and Western blots, immunohistology, and flow cytometry to examine the distribution of PCDH12 in mouse tissues. It is an N-glycosylated protein of 150-kDa mass. In the endothelium, PCDH12 immunoreactivity was variable and dependent upon the vascular bed. In both the embryo and embryonic stem cell differentiation system, signals were localized in vasculogenic rather than angiogenic endothelium. In addition, the protein was strongly expressed in a subset of invasive cells of the placenta, which were identified as glycogen-rich trophoblasts. In adult mice, strong PCDH12 signals were observed in mesangial cells of kidney glomeruli whereas expression was not detected in other types of perivascular cells. As opposed to most protocadherins, PCDH12 is not expressed in early embryonic (day 12.5) and adult brains. As a first approach to obtain insight into PCDH12 function, we produced transgenic mice deficient in PCDH12, which were viable and fertile. They did not display any obvious histomorphological defects. We conclude that PCDH12 has a unique expression pattern and that its deficiency does not lead to conspicuous abnormalities. Moreover, PCDH12 is the first specific marker for both glycogen-rich trophoblasts and mesangial cells.


Subject(s)
Cadherins/metabolism , Endothelial Cells/metabolism , Glomerular Mesangium/metabolism , Trophoblasts/metabolism , Animals , Biomarkers , Cadherins/biosynthesis , Cadherins/genetics , Cell Differentiation/genetics , Cell Line , Endothelial Cells/cytology , Female , Gene Expression Regulation, Developmental/genetics , Glomerular Mesangium/cytology , Glycogen/metabolism , Male , Mice , Mice, Knockout , Pluripotent Stem Cells/cytology , Pluripotent Stem Cells/metabolism , Protocadherins , Trophoblasts/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...